{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:46:21Z","timestamp":1790621181078,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"DOI":"10.1186\/s40842-025-00252-6","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T23:02:31Z","timestamp":1765753351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["SGLT2 inhibitors in cardiac amyloidosis: mechanistic insights and clinical perspectives\u2014a narrative review"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-1323","authenticated-orcid":false,"given":"B\u00fclent","family":"\u00d6zlek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veysel Ozan","family":"Tanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"252_CR1","doi-asserted-by":"publisher","first-page":"1477988","DOI":"10.3389\/fmed.2024.1477988","volume":"11","author":"S Senigarapu","year":"2024","unstructured":"Senigarapu S, Driscoll JJ. A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis. Front Med (Lausanne). 2024;11:1477988. https:\/\/doi.org\/10.3389\/fmed.2024.1477988.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"252_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.6515\/ACS.202307_39(4).20230610A","volume":"39","author":"CC Wang","year":"2023","unstructured":"Wang CC, Chang WT, Lin YH, Tzeng BH, Chao TH, Hung CL, Wu YW, Tsai CH, Lin WW, Chang KC, Chang HY, Yu WC, Wang WH, Cheng CI, Wang TD, Hou CJ, Chen WJ. 2023 expert consensus of the Taiwan society of cardiology on the diagnosis and treatment of cardiac amyloidosis. Acta Cardiol Sin. 2023;39(4):511\u201343. https:\/\/doi.org\/10.6515\/ACS.202307_39(4).20230610A.","journal-title":"Acta Cardiol Sin"},{"issue":"11","key":"252_CR3","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ejhf.2974","volume":"25","author":"P Elliott","year":"2023","unstructured":"Elliott P, Gundapaneni B, Sultan MB, Ines M, Garcia-Pavia P. Improved long-term survival with Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms. Eur J Heart Fail. 2023;25(11):2060\u20134. https:\/\/doi.org\/10.1002\/ejhf.2974.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"252_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ajh.27177","volume":"99","author":"MA Gertz","year":"2024","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. Am J Hematol. 2024;99(2):309\u201324. https:\/\/doi.org\/10.1002\/ajh.27177.","journal-title":"Am J Hematol"},{"issue":"4","key":"252_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jcmg.2024.10.011","volume":"18","author":"M Fontana","year":"2025","unstructured":"Fontana M, Ioannou A, Cuddy S, Dorbala S, Masri A, Moon JC, Singh V, Clerc O, Hanna M, Ruberg F, Grogan M, Emdin M, Gillmore J. The last decade in cardiac amyloidosis: advances in Understanding Pathophysiology, diagnosis and Quantification, Prognosis, treatment Strategies, and monitoring response. JACC Cardiovasc Imaging. 2025;18(4):478\u201399. https:\/\/doi.org\/10.1016\/j.jcmg.2024.10.011.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"37","key":"252_CR6","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"15","key":"252_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, B\u00f6hm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F. EMPEROR-Reduced trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"16","key":"252_CR8","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pi\u00f1a IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M. EMPEROR-Preserved trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"12","key":"252_CR9","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O\u2019Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilder\u00e4ng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM. DELIVER trial committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"issue":"1","key":"252_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12933-025-02767-9","volume":"24","author":"F Cinti","year":"2025","unstructured":"Cinti F, Laborante R, Cappannoli L, Morciano C, Gugliandolo S, Pontecorvi A, Burzotta F, Donniacuo M, Cappetta D, Patti G, Giaccari A, D\u2019Amario D. The effects of SGLT2 inhibitors on cardiac metabolism in patients with hfpef: fact or fiction? Cardiovasc Diabetol. 2025;24(1):208. https:\/\/doi.org\/10.1186\/s12933-025-02767-9.","journal-title":"Cardiovasc Diabetol"},{"key":"252_CR11","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.15420\/cfr.2024.33","volume":"11","author":"G Panichella","year":"2025","unstructured":"Panichella G, Aimo A, Castiglione V, Vergaro G, Emdin M. Heart failure management in cardiac amyloidosis: towards a paradigm shift. Card Fail Rev. 2025;11:e15. https:\/\/doi.org\/10.15420\/cfr.2024.33.","journal-title":"Card Fail Rev"},{"issue":"6","key":"252_CR12","doi-asserted-by":"publisher","first-page":"e14392","DOI":"10.1111\/eci.14392","volume":"55","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Theofilis P, Patoulias D, Schuermans A, Vlachakis PK, Klisic A, Rizzo M, Fragakis N. Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: systematic review and meta-analysis. Eur J Clin Invest. 2025;55(6):e14392. https:\/\/doi.org\/10.1111\/eci.14392.","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"252_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.4330\/wjc.v16.i7.370","volume":"16","author":"C Kourek","year":"2024","unstructured":"Kourek C, Briasoulis A, Magouliotis DE, Georgoulias P, Giamouzis G, Triposkiadis F, Skoularigis J, Xanthopoulos A. Recent advances in the diagnostic methods and therapeutic strategies of transthyretin cardiac amyloidosis. World J Cardiol. 2024;16(7):370\u20139. https:\/\/doi.org\/10.4330\/wjc.v16.i7.370.","journal-title":"World J Cardiol"},{"issue":"5","key":"252_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jchf.2025.03.017","volume":"13","author":"JM Griffin","year":"2025","unstructured":"Griffin JM, Grodin JL, Ruberg FL, Masri A, Hanna M, Maurer MS. Current landscape of therapies for transthyretin amyloid cardiomyopathy. JACC Heart Fail. 2025;13(5):685\u201394. https:\/\/doi.org\/10.1016\/j.jchf.2025.03.017.","journal-title":"JACC Heart Fail"},{"issue":"31","key":"252_CR15","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","volume":"44","author":"A Ioannou","year":"2023","unstructured":"Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, Jiang A, Cabras G, Filisetti S, Bolhuis RE, Bandera F, Venneri L, Martinez-Naharro A, Law S, Kotecha T, Virsinskaite R, Knight DS, Emdin M, Petrie A, Lachmann H, Wechelakar A, Petrie M, Hughes A, Freemantle N, Hawkins PN, Whelan C, McMurray JJV, Gillmore JD, Fontana M. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023;44(31):2893\u2013907. https:\/\/doi.org\/10.1093\/eurheartj\/ehad347.","journal-title":"Eur Heart J"},{"key":"252_CR16","doi-asserted-by":"publisher","first-page":"131813","DOI":"10.1016\/j.ijcard.2024.131813","volume":"402","author":"Y Kang","year":"2024","unstructured":"Kang Y, Qu N, Zhang Z, Zhang Q, Chen X, Fu M. Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis. Int J Cardiol. 2024;402:131813. https:\/\/doi.org\/10.1016\/j.ijcard.2024.131813.","journal-title":"Int J Cardiol"},{"issue":"4","key":"252_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/03007995.2025.2495167","volume":"41","author":"P Karakasis","year":"2025","unstructured":"Karakasis P. Sodium-glucose cotransporter 2 inhibitors in transthyretin amyloid cardiomyopathy: navigating potential benefits and uncertainties. Curr Med Res Opin. 2025;41(4):657\u201361. https:\/\/doi.org\/10.1080\/03007995.2025.2495167.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"252_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","volume":"5","author":"KM Talha","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: A review of current evidence. Int J Heart Fail. 2023;5(2):82\u201390. https:\/\/doi.org\/10.36628\/ijhf.2022.0030.","journal-title":"Int J Heart Fail"},{"issue":"21","key":"252_CR19","doi-asserted-by":"publisher","first-page":"11458","DOI":"10.3390\/ijms252111458","volume":"25","author":"S Prosperi","year":"2024","unstructured":"Prosperi S, D\u2019Amato A, Labbro Francia A, Monosilio S, Cesti\u00e8 C, Marek Iannucci S, Netti L, Angotti D, Filomena D, Mariani MV, Myftari V, German\u00f2 R, Cimino S, Mancone M, Badagliacca R, Maestrini V, Severino P, Vizza CD. Sodium-Glucose cotransporter 2 inhibitor therapy in different scenarios of heart failure: an overview of the current literature. Int J Mol Sci. 2024;25(21):11458. https:\/\/doi.org\/10.3390\/ijms252111458.","journal-title":"Int J Mol Sci"},{"key":"252_CR20","doi-asserted-by":"publisher","first-page":"108861","DOI":"10.1016\/j.pharmthera.2025.108861","volume":"270","author":"M Armillotta","year":"2025","unstructured":"Armillotta M, Angeli F, Paolisso P, Belmonte M, Raschi E, Di Dalmazi G, Amicone S, Canton L, Fedele D, Suma N, Fo\u00e0 A, Bergamaschi L, Pizzi C. Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure. Pharmacol Ther. 2025;270:108861. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108861.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"252_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u201372. https:\/\/doi.org\/10.1038\/s41569-020-0406-8.","journal-title":"Nat Rev Cardiol"},{"key":"252_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","volume":"6","author":"Y Maejima","year":"2020","unstructured":"Maejima Y. SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function. Front Cardiovasc Med. 2020;6:186. https:\/\/doi.org\/10.3389\/fcvm.2019.00186.","journal-title":"Front Cardiovasc Med"},{"key":"252_CR23","doi-asserted-by":"publisher","first-page":"1291450","DOI":"10.3389\/fcvm.2023.1291450","volume":"10","author":"S Su","year":"2023","unstructured":"Su S, Ji X, Li T, Teng Y, Wang B, Han X, Zhao M. The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy. Front Cardiovasc Med. 2023;10:1291450. https:\/\/doi.org\/10.3389\/fcvm.2023.1291450.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"252_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00395-025-01115-y","volume":"120","author":"M Wang","year":"2025","unstructured":"Wang M, Preckel B, Zuurbier CJ, Weber NC. Effects of SGLT2 inhibitors on ion channels in heart failure: focus on the endothelium. Basic Res Cardiol. 2025;120(4):779\u201398. https:\/\/doi.org\/10.1007\/s00395-025-01115-y.","journal-title":"Basic Res Cardiol"},{"issue":"24","key":"252_CR25","doi-asserted-by":"publisher","first-page":"e176708","DOI":"10.1172\/JCI176708","volume":"134","author":"L Goedeke","year":"2024","unstructured":"Goedeke L, Ma Y, Gaspar RC, Nasiri A, Lee J, Zhang D, Galsgaard KD, Hu X, Zhang J, Guerrera N, Li X, LaMoia T, Hubbard BT, Haedersdal S, Wu X, Stack J, Dufour S, Butrico GM, Kahn M, Perry RJ, Cline GW, Young LH, Shulman GI. SGLT2 Inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. J Clin Invest. 2024;134(24):e176708. https:\/\/doi.org\/10.1172\/JCI176708.","journal-title":"J Clin Invest"},{"issue":"1","key":"252_CR26","doi-asserted-by":"publisher","first-page":"23313","DOI":"10.1038\/s41598-024-74289-5","volume":"14","author":"P Simon","year":"2024","unstructured":"Simon P, Behrens HM, Kristen A, R\u00f6cken C. Myocardial inflammatory cells in cardiac amyloidosis. Sci Rep. 2024;14(1):23313. https:\/\/doi.org\/10.1038\/s41598-024-74289-5.","journal-title":"Sci Rep"},{"issue":"1","key":"252_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12933-025-02777-7","volume":"24","author":"TT Yoo","year":"2025","unstructured":"Yoo TT, Baek IH, Stoletniy L, Hilliard A, Sakr A, Doycheva D. Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. Cardiovasc Diabetol. 2025;24(1):227. https:\/\/doi.org\/10.1186\/s12933-025-02777-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"252_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12933-024-02312-0","volume":"23","author":"HY Duan","year":"2024","unstructured":"Duan HY, Barajas-Martinez H, Antzelevitch C, Hu D. The potential anti-arrhythmic effect of SGLT2 inhibitors. Cardiovasc Diabetol. 2024;23(1):252. https:\/\/doi.org\/10.1186\/s12933-024-02312-0.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"252_CR29","doi-asserted-by":"publisher","first-page":"30764","DOI":"10.1038\/s41598-024-80829-w","volume":"14","author":"HX Ma","year":"2024","unstructured":"Ma HX, Wu K, Dong FH, Cai BK, Wu D, Lu HY. Effects of empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction. Sci Rep. 2024;14(1):30764. https:\/\/doi.org\/10.1038\/s41598-024-80829-w.","journal-title":"Sci Rep"},{"key":"252_CR30","doi-asserted-by":"publisher","first-page":"917761","DOI":"10.3389\/fendo.2022.917761","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Ding L, Tian L, Tian Y, Liao L, Zhao J. Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies. Front Endocrinol (Lausanne). 2022;13:917761. https:\/\/doi.org\/10.3389\/fendo.2022.917761.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"252_CR31","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.34067\/KID.0000000600","volume":"5","author":"R Chowdhury","year":"2024","unstructured":"Chowdhury R, Shah S, Latcha S, Lobato L. Kidney disease in systemic amyloidosis: A review of amyloid, amyloid serum A Protein, leukocyte chemotactic factor 2, and transthyretin amyloid. Kidney360. 2024;5(12):1925\u201337. https:\/\/doi.org\/10.34067\/KID.0000000600.","journal-title":"Kidney360"},{"issue":"5","key":"252_CR32","doi-asserted-by":"publisher","first-page":"771","DOI":"10.34067\/KID.0000000000000425","volume":"5","author":"A Upadhyay","year":"2024","unstructured":"Upadhyay A. SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback. Kidney360. 2024;5(5):771\u201382. https:\/\/doi.org\/10.34067\/KID.0000000000000425.","journal-title":"Kidney360"},{"issue":"1","key":"252_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/jcm13010283","volume":"13","author":"MJ Steinhardt","year":"2024","unstructured":"Steinhardt MJ, Cejka V, Chen M, B\u00e4uerlein S, Sch\u00e4fer J, Adrah A, Ihne-Schubert SM, Papagianni A, Kort\u00fcm KM, Morbach C, St\u00f6rk S. Safety and tolerability of SGLT2 inhibitors in cardiac Amyloidosis-A clinical feasibility study. J Clin Med. 2024;13(1):283. https:\/\/doi.org\/10.3390\/jcm13010283.","journal-title":"J Clin Med"},{"issue":"7","key":"252_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3949\/ccjm.91a.23093","volume":"91","author":"R Jaswaney","year":"2024","unstructured":"Jaswaney R, Sokoloff S, Rakita V, Rubin DJ. SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists. Cleve Clin J Med. 2024;91(7):415\u201323. https:\/\/doi.org\/10.3949\/ccjm.91a.23093.","journal-title":"Cleve Clin J Med"},{"key":"252_CR35","doi-asserted-by":"publisher","unstructured":"Tang L, Zhao W, Li K, Tian L, Zhou X, Guo H, Zeng M. Assessing microvascular dysfunction and predicting long-term prognosis in patients with cardiac amyloidosis by cardiovascular magnetic resonance quantitative stress perfusion. J Cardiovasc Magn Reson. 2025 Summer;27(1):101134. https:\/\/doi.org\/10.1016\/j.jocmr.2024.101134.","DOI":"10.1016\/j.jocmr.2024.101134"},{"issue":"4","key":"252_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.55729\/2000-9666.1505","volume":"15","author":"MHBA Maik","year":"2025","unstructured":"Maik MHBA, Ibtisam M, Sheikh S, Malik MABA, Ihsan A, Arham M, Haq U, Parveen A. The role of SGLT2 inhibitors in atherosclerosis: A systematic review. J Community Hosp Intern Med Perspect. 2025;15(4):29\u201333. https:\/\/doi.org\/10.55729\/2000-9666.1505.","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"6","key":"252_CR37","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/life12060803","volume":"12","author":"CA Adam","year":"2022","unstructured":"Adam CA, Anghel R, Marcu DTM, Mitu O, Roca M, Mitu F. Impact of sodium-Glucose cotransporter 2 (SGLT2) inhibitors on arterial stiffness and vascular Aging-What do we know so far? (A narrative Review). Life (Basel). 2022;12(6):803. https:\/\/doi.org\/10.3390\/life12060803.","journal-title":"Life (Basel)"},{"issue":"1","key":"252_CR38","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s12933-024-02491-w","volume":"23","author":"SO G\u00f6pel","year":"2024","unstructured":"G\u00f6pel SO, Adingupu D, Wang J, Semenova E, Behrendt M, Jansson-L\u00f6fmark R, Ahlstr\u00f6m C, J\u00f6nsson-Rylander AC, Gopaul VS, Esterline R, Gan LM, Xiao RP. SGLT2 Inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling. Cardiovasc Diabetol. 2024;23(1):408. https:\/\/doi.org\/10.1186\/s12933-024-02491-w.","journal-title":"Cardiovasc Diabetol"},{"key":"252_CR39","doi-asserted-by":"publisher","first-page":"110072","DOI":"10.1016\/j.intimp.2023.110072","volume":"118","author":"Y Chen","year":"2023","unstructured":"Chen Y, Peng D. New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling. Int Immunopharmacol. 2023;118:110072. https:\/\/doi.org\/10.1016\/j.intimp.2023.110072.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"252_CR40","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","volume":"128","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res. 2021;128(10):1554\u201375. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318187.","journal-title":"Circ Res"},{"issue":"5","key":"252_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","volume":"18","author":"S Pabel","year":"2021","unstructured":"Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 inhibitors and their mode of action in heart Failure-Has the mystery been unravelled? Curr Heart Fail Rep. 2021;18(5):315\u201328. https:\/\/doi.org\/10.1007\/s11897-021-00529-8.","journal-title":"Curr Heart Fail Rep"},{"issue":"1","key":"252_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-025-02756-y","volume":"24","author":"A Ovchinnikov","year":"2025","unstructured":"Ovchinnikov A, Potekhina A, Filatova A, Svirida O, Zherebchikova K, Ageev F, Belyavskiy E. Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial. Cardiovasc Diabetol. 2025;24(1):196. https:\/\/doi.org\/10.1186\/s12933-025-02756-y.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"252_CR43","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.amjmed.2025.02.010","volume":"138","author":"SN Augusto Jr","year":"2025","unstructured":"Augusto SN Jr, Issa R, Vanhentenrijk S, Kaelber D, Tang WHW. Sodium-Glucose cotransporter 2 inhibitors in patients with amyloidosis with or without heart failure. Am J Med. 2025;138(6):980\u20136. https:\/\/doi.org\/10.1016\/j.amjmed.2025.02.010.","journal-title":"Am J Med"},{"key":"252_CR44","doi-asserted-by":"publisher","first-page":"133567","DOI":"10.1016\/j.ijcard.2025.133567","volume":"438","author":"AK Mahmoud","year":"2025","unstructured":"Mahmoud AK, Kamel I, Awad K, Farina J, Ibrahim R, Abdelnabi M, Allam M, Pham HN, Rosenthal J, Steidley E, Lester SJ, Horn B, Ayoub C, Arsanjani R. The complementary effects of GLP-1 receptor agonists and SGLT2 inhibitors in transthyretin cardiac amyloidosis patients: A retrospective multicenter cohort study. Int J Cardiol. 2025;438:133567. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133567.","journal-title":"Int J Cardiol"},{"key":"252_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.amjcard.2025.01.012","volume":"243","author":"SH Byer","year":"2025","unstructured":"Byer SH, Sivamurugan A, Grewal US, Fradley MG, Dominic P. Impact of Sodium-Glucose Cotransporter-2 inhibitors on cardiovascular outcomes in transthyretin amyloid cardiomyopathy. Am J Cardiol. 2025;243:15\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2025.01.012.","journal-title":"Am J Cardiol"},{"issue":"12","key":"252_CR46","doi-asserted-by":"publisher","first-page":"101405","DOI":"10.1016\/j.jacadv.2024.101405","volume":"3","author":"V Jaiswal","year":"2024","unstructured":"Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose cotransporter 2 inhibitor use and outcomes in transthyretin amyloid cardiomyopathy. JACC Adv. 2024;3(12):101405. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101405.","journal-title":"JACC Adv"},{"issue":"6","key":"252_CR47","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.hrthm.2024.09.002","volume":"22","author":"A Sivamurugan","year":"2025","unstructured":"Sivamurugan A, Byer SH, Grewal US, Dominic P. Impact of SGLT2 inhibitors on the outcomes of patients with cardiac arrhythmias and transthyretin cardiac amyloidosis. Heart Rhythm. 2025;22(6):1615\u20136. https:\/\/doi.org\/10.1016\/j.hrthm.2024.09.002.","journal-title":"Heart Rhythm"},{"issue":"19","key":"252_CR48","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.3390\/jcm13195966","volume":"13","author":"N Schwegel","year":"2024","unstructured":"Schwegel N, Toferer C, Zach DK, Santner V, H\u00f6ller V, Lugitsch J, Wallner M, Gollmer J, Aziz F, von Lewinski D, Kolesnik E, Ablasser K, Zirlik A, Sourij H, Verheyen N. Impact of SGLT2-Inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy: analysis of a prospective registry study. J Clin Med. 2024;13(19):5966. https:\/\/doi.org\/10.3390\/jcm13195966.","journal-title":"J Clin Med"},{"issue":"3","key":"252_CR49","doi-asserted-by":"publisher","first-page":"26081","DOI":"10.31083\/RCM26081","volume":"26","author":"N Ermolaev","year":"2025","unstructured":"Ermolaev N, Willixhofer R, Krall C, Kronberger C, Rettl R, Binder C, Duca F, Nitsche C, Kammerlander A, Poledniczek M, Gregshammer B, Ahmadi-Fazel D, Eslami M, Ligios LC, Kastner J, Bergler-Klein J. Badr Eslam R. Potential hematopoietic effects of SGLT2 inhibitors in patients with cardiac amyloidosis. Rev Cardiovasc Med. 2025;26(3):26081. https:\/\/doi.org\/10.31083\/RCM26081.","journal-title":"Rev Cardiovasc Med"},{"issue":"24","key":"252_CR50","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","volume":"83","author":"A Porcari","year":"2024","unstructured":"Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, Bordignon L, Masri A, Serenelli M, Urey M, Musumeci B, Cipriani A, Canepa M, Badr-Eslam R, Kronberger C, Chimenti C, Zampieri M, Allegro V, Razvi Y, Patel R, Ioannou A, Rauf MU, Petrie A, Whelan C, Emdin M, Metra M, Merlo M, Sinagra G, Hawkins PN, Solomon SD, Gillmore JD, Fontana M. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2024;83(24):2411\u201322. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.429.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"252_CR51","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.cardfail.2024.06.009","volume":"30","author":"FM Lang","year":"2024","unstructured":"Lang FM, Teruya S, Cuomo M, Santos AM, Radhakrishnan J, Lentzsch S, Chakraborty R, Bhutani D, Maurer MS. Safety and efficacy of SGLT2 inhibitors for amyloid Light-Chain cardiomyopathy. J Card Fail. 2024;30(12):1641\u20136. https:\/\/doi.org\/10.1016\/j.cardfail.2024.06.009.","journal-title":"J Card Fail"},{"issue":"4","key":"252_CR52","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/ejhf.3198","volume":"26","author":"FM Lang","year":"2024","unstructured":"Lang FM, Teruya S, Weinsaft A, Cuomo M, Santos AM, Nalbandian A, Bampatsias D, Maurer MS. Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety. Eur J Heart Fail. 2024;26(4):938\u201347. https:\/\/doi.org\/10.1002\/ejhf.3198.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"252_CR53","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ehf2.14188","volume":"10","author":"S Dobner","year":"2023","unstructured":"Dobner S, Bernhard B, Asatryan B, Windecker S, Stortecky S, Pilgrim T, Gr\u00e4ni C, Hunziker L. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to Dapagliflozin. ESC Heart Fail. 2023;10(1):397\u2013404. https:\/\/doi.org\/10.1002\/ehf2.14188.","journal-title":"ESC Heart Fail"},{"issue":"10","key":"252_CR54","doi-asserted-by":"publisher","first-page":"e72725","DOI":"10.7759\/cureus.72725","volume":"16","author":"A Pillai","year":"2024","unstructured":"Pillai A, Riaz S, Arora S, Jaiswal A. The role of Sodium-Glucose Cotransporter-2 inhibitors in adults with transthyretin cardiac amyloidosis: A Single-Center retrospective cohort study. Cureus. 2024;16(10):e72725. https:\/\/doi.org\/10.7759\/cureus.72725.","journal-title":"Cureus"},{"issue":"4","key":"252_CR55","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s11739-022-02944-8","volume":"17","author":"M Zampieri","year":"2022","unstructured":"Zampieri M, Argir\u00f2 A, Allinovi M, Perfetto F, Cappelli F. SGLT2 inhibitors in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. Intern Emerg Med. 2022;17(4):1243\u20135. https:\/\/doi.org\/10.1007\/s11739-022-02944-8.","journal-title":"Intern Emerg Med"},{"issue":"10","key":"252_CR56","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/pds.5496","volume":"31","author":"CM Lewellyan","year":"2022","unstructured":"Lewellyan CM, Spoutz P, Schaefer M, Patterson ME. Risk of volume depletion events with concomitant use of sodium glucose co-transporter 2 inhibitors and loop diuretics: A self-controlled case series study. Pharmacoepidemiol Drug Saf. 2022;31(10):1102\u20139. https:\/\/doi.org\/10.1002\/pds.5496.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"252_CR57","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.ekir.2022.08.016","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(11):2546\u20137. https:\/\/doi.org\/10.1016\/j.ekir.2022.08.016.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"252_CR58","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/M22-2904","volume":"176","author":"SD Navaneethan","year":"2023","unstructured":"Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Liew A, Michos ED, Olowu WA, Sadusky T, Tandon N, Tuttle KR, Wanner C, Wilkens KG, Craig JC, Tunnicliffe DJ, Tonelli M, Cheung M, Earley A, Rossing P, de Boer IH, Khunti K. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023;176(3):381\u20137. https:\/\/doi.org\/10.7326\/M22-2904.","journal-title":"Ann Intern Med"},{"issue":"6S","key":"252_CR59","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.jchf.2023.12.023","volume":"12","author":"J Butler","year":"2024","unstructured":"Butler J, Anderson JE. Managing patients on SGLT2 inhibitors in primary care. JACC Heart Fail. 2024;12(6S):S7\u20139. https:\/\/doi.org\/10.1016\/j.jchf.2023.12.023.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"252_CR60","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1161\/CIRCULATIONAHA.122.060823","volume":"146","author":"K Umanath","year":"2022","unstructured":"Umanath K, Testani JM, Lewis JB. Dip in eGFR: stay the course with SGLT-2 Inhibition. Circulation. 2022;146(6):463\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060823.","journal-title":"Circulation"},{"key":"252_CR61","doi-asserted-by":"publisher","first-page":"1366439","DOI":"10.3389\/fphar.2024.1366439","volume":"15","author":"A Alsalem","year":"2024","unstructured":"Alsalem A, Alsultan MM, Alqarni F, Almangour A, Alsharekh L, Alenazi S, Alzahrani S, Almanqour RA, Alazmi A, Alzahrani A. Real-world evidence of the effects of sodium-glucose co-transporter 2 inhibitors on the dosing of diuretics in patients with heart failure: a retrospective cohort study. Front Pharmacol. 2024;15:1366439. https:\/\/doi.org\/10.3389\/fphar.2024.1366439.","journal-title":"Front Pharmacol"},{"issue":"11","key":"252_CR62","doi-asserted-by":"publisher","first-page":"e73320","DOI":"10.7759\/cureus.73320","volume":"16","author":"Y Mori","year":"2024","unstructured":"Mori Y, Kenzaka T. Systemic amyloid light chain amyloidosis with repeated syncope due to severe orthostatic hypotension caused by autonomic neuropathy: A case report. Cureus. 2024;16(11):e73320. https:\/\/doi.org\/10.7759\/cureus.73320.","journal-title":"Cureus"},{"issue":"8","key":"252_CR63","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1007\/s12325-022-02169-3","volume":"39","author":"NB Jhalani","year":"2022","unstructured":"Jhalani NB. Clinical considerations for use of SGLT2 inhibitor therapy in patients with heart failure and reduced ejection fraction: A review. Adv Ther. 2022;39(8):3472\u201387. https:\/\/doi.org\/10.1007\/s12325-022-02169-3.","journal-title":"Adv Ther"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00252-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00252-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00252-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T23:02:32Z","timestamp":1765753352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-025-00252-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["252"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00252-6","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a narrative review and did not involve human participants or animal experiments; therefore, ethics approval and informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}